NCT00194532

Cefpodoxime vs Ciprofloxacin for Acute Cystitis

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 300 (actual)
• Sponsor: University of Washington · Academic / Other
• Sex: Female
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

Urinary tract infection (UTI) is a very common problem in young healthy women, afflicting approximately one-half of women by their late 20s. One of the most common antibiotics used to treat UTIs is ciprofloxacin, usually for a total of three days. However, increasing resistance to this antibiotic has raised concerns about its overuse for cystitis and generated interest in alternative agents. An alternative antibiotic which is approved for use in UTIs is cefpodoxime. However, there are few studies evaluating the efficacy and tolerance of this compound when given in a 3-day regimen as is commonly used for treatment of UTI. The major purpose of this study is to assess the efficacy and tolerance of a 3-day regimen of cefpodoxime versus ciprofloxacin for treatment of acute uncomplicated cystitis.

Detailed description

Procedures subjects will undergo once they have read and signed the consent are: Questions about their medical and sexual history and current symptoms of UTI. They will be asked to provide a urine and peri-urethral sample and then are randomly assigned to one of the two treatment groups.They will be given a sheet to record symptoms at home. They will be asked to return to the clinic in 5-9 and 28-30 days after completing antibiotic therapy.Follow-up questions will be asked and urine and peri-urethral will be self collected at each visit.

Conditions

• Urinary Tract Infection

Interventions

Type	Name	Description
DRUG	Cefpodoxime	Cefpodoxime 100mg twice a day(BID)for 3 days
DRUG	Ciprofloxacin	Ciprofloxacin 250mg twice a day (BID)for 3 days

Timeline

• Start date: 2005-06-01
• Primary completion: 2009-02-01
• Completion: 2009-02-01
• First posted: 2005-09-19
• Last updated: 2014-06-10
• Results posted: 2011-04-28

Locations

2 sites across 1 country: United States